ArticlePLoS neglected tropical diseases2026
A retrospective study on Chagas disease detection and management in Tremedal and Novo Horizonte: Insights prior to the Oxente Chagas Bahia Project.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease (CD) remains a persistent public health challenge in endemic areas of Brazil, where access to diagnosis, clinical staging, and etiological treatment is often limited. Tremedal and Novo Horizonte, municipalities in the state of Bahia, continue to report chronic cases despite advances in vector control. This study provides a retrospective assessment of CD detection and clinical management in these municipalities prior to the full implementation of the Oxente Chagas Bahia Project. We analyzed individuals tested for CD serology between 2019 and 2023 using data from the Laboratory Environment Manager (GAL) system and electronic primary care records (e-SUS). Sociodemographic characteristics, seropositivity, turnaround time for serological testing, and clinical manifestations were evaluated. A total of 472 individuals underwent serological testing. Testing volume increased markedly in Tremedal over time, whereas Novo Horizonte initiated screening only in 2023. Fourteen individuals (3.0%) tested positive for anti-Trypanosoma cruzi antibodies, all from Tremedal; 13 were included in the clinical analysis. The median age of confirmed cases was 52 years, and 61.5% were female. Among the 13 confirmed cases, the indeterminate form predominated (61.5%), followed by the cardiac and mixed forms (15.4% each) and the digestive form (7.7%) Electrocardiographic conduction abnormalities predominated among individuals with cardiac involvement, while severe digestive manifestations, including megacolon and megaesophagus, were documented in three individuals. Median turnaround time for serological results was longer in Tremedal than in Novo Horizonte. Documentation of etiological treatment with benznidazole was limited, with treatment records identified for only two of the thirteen confirmed cases in the available medical records. These findings highlight the ongoing burden of chronic CD, substantial gaps in screening and treatment, and the need to strengthen diagnostic access and guideline-based management. This study establishes a critical pre-intervention baseline for evaluating the impact of the Oxente Chagas Bahia Project in endemic municipalities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.